Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 7/20 | 0.52 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enefexine SCHEMBL4886231 | 0.98 | SLC18A3 (0.53) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL27469424 | 0.89 | HTR3A (0.59) | HTR3A | |
| SCHEMBL23763865 | 0.89 | HTR3A (0.59) | HTR3A | |
| SCHEMBL4321926 | 0.85 | SPHK1 (0.50) | SPHK1 | |
| SCHEMBL7917964 | 0.85 | SLC18A3 (0.52) | SLC18A3SIGMAR1HTR2CQDPRSPHK1 | |
| Enefexine SCHEMBL11444275 | 0.84 | SLC18A3 (0.45) | SLC18A3SIGMAR1HTR2CQDPRHTR6 | |
| SCHEMBL7954468 | 0.83 | QDPR (0.47) | SLC18A3SIGMAR1HTR2CQDPRHTR3A | |
| SCHEMBL944936 | 0.82 | SPHK1 (0.58) | SLC18A3SIGMAR1HTR2CSPHK1 | |
| SCHEMBL7358862 | 0.81 | ALDH1A1 (0.45) | HTR2CSPHK1 | |
| SCHEMBL8284796 | 0.80 | SLC18A3 (0.47) | SLC18A3SIGMAR1HTR2CQDPRHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-102143961-B | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2014-11-05 | — | — | CN | claimed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | claimed |
| JP-2011526251-A | — | — | 2011-10-06 | — | — | JP | claimed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | claimed |
| CN-102143961-A | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON INC | 2011-08-03 | — | — | CN | claimed |
| EP-2310386-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2011-04-20 | — | — | EP | claimed |
| EP-1883451-B9 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC (CA) | 2011-02-09 | — | — | EP | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007017764-A2 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS WITH DUAL NOS INHIBITORY ACTIVITY AND MUOPIOID AGONIST ACTIVITY | NEURAXON, INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| EP-1737473-A2 | LITHIUM COMBINATIONS, AND USES RELATED THERETO | Satow, Philip, Maxwell (US) | 2007-01-03 | — | — | EP | claimed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | claimed |
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| WO-2005102366-A2 | LITHIUM COMBINATIONS, AND USES RELATED THERETO | SATOW PHILIP MAXWELL (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050233010-A1 | Lithium combinations, and uses related thereto | NOVEN THERAPEUTICS, LLC | 2005-10-20 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-4188396-A | ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1980-02-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | GRIN3A, GRIN2A, BDNF | SLC18A3 99/4885SIGMAR1 855/4885HTR2C 157/4885 |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | SLC18A3 506/4885SIGMAR1 777/4885HTR2C 434/4885 |
| US-20050233010-A1 | Lithium combinations, and uses related thereto | NPY4R, ADRA1D, HTR4 | SLC18A3 393/4885SIGMAR1 308/4885HTR2C 88/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | SLC18A3 506/4885SIGMAR1 777/4885HTR2C 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.